The Cass Review has been widely discredited internationally, with gender specialists, clinicians, and researchers rejecting its methodology and conclusions. Its suggestion that puberty blockers might serve conversion therapy purposes has been called out as particularly harmful, inverting the evidence and misrepresenting what gender-affirming care actually does.
What is the Cass Review, and why does it matter?
In 2024, Dr Hilary Cass published her independent review of gender identity services for children and young people in England. It was commissioned by NHS England, and its findings were used almost immediately to justify sweeping restrictions on gender-affirming care for trans young people in the UK, including a ban on puberty blockers on private prescription. That ban has since spread beyond the UK, with other governments citing Cass as justification for their own restrictions.
This is why the international discrediting of the review matters so much. It was not just an academic debate: the review had direct, immediate, measurable consequences for real young people who lost access to care that was helping them. The harm caused by those restrictions is not hypothetical. Trans young people, their families, and the clinicians who cared for them have described the impact in clear, painful terms.
What did international experts find wrong with it?
The criticisms from the international clinical and research community have been substantial and consistent. Researchers whose own work was cited in the Cass Review publicly objected to how their findings were characterised and used. Clinicians in countries with longer-established gender-affirming care programmes rejected the review's framing of the evidence. Specialists in evidence-based medicine identified serious problems with how studies were included, excluded, and weighted.
One of the most significant structural criticisms is that the review applied an unusually high evidentiary bar to gender-affirming care that would simply not be applied to other areas of medicine. Evidence that would be considered sufficient to justify treatment in any other paediatric context was dismissed as insufficient when it came to puberty blockers. That asymmetry is not a neutral methodological choice. It reflects a pre-existing scepticism towards the care itself, and the effect is to make gender-affirming treatment appear uniquely unproven when in fact the evidence base is comparable to, and in some respects stronger than, many accepted paediatric interventions.
There is also a pattern in the sources the review relied upon. Some of the research it treated most favourably comes from networks that have been identified as functioning as gatekeeping organisations rather than independent scientific bodies. The Society for Evidence-Based Gender Medicine, known as SEGM, is the clearest example: it presents as a research network but consistently produces work aimed at restricting access to gender-affirming care, and several of the studies the Cass Review elevated were linked to that network. When the evidentiary house is built on those foundations, the conclusions it reaches are not surprising, but they are not trustworthy either.
The conversion therapy claim: what Cass suggested and why it is wrong
One of the most troubling elements of the Cass Review is the suggestion that puberty blockers could function as a form of conversion therapy. Hilary Cass raised the possibility that suppressing puberty might, in some cases, prevent a young person from developing in a direction that would have led them to identify as gay or lesbian rather than trans, and that blocking that development could therefore be understood as redirecting identity.
That framing is an inversion of what the evidence shows, and it is an inversion of what puberty blockers do.
Puberty blockers pause an unwanted physical process. They do not alter who a person is. They do not suppress attraction, or redirect identity, or change the direction in which a young person's sense of self is developing. They simply prevent the body from changing in ways that are causing significant distress. The young person's identity continues to develop during that time, as it would for any young person, and research consistently shows that young people given time and space to explore their identity do exactly that. Many go on to pursue further medical transition. Some do not. Both outcomes are valid, and the blocker did not determine either.
Conversion therapy, by contrast, is an attempt to change or suppress who a person is. It involves directing psychological or social pressure at a person's identity, their attractions, their sense of gender, with the explicit aim of making them conform to a different identity. It causes serious harm. The evidence on that is not contested. Major psychological and psychiatric bodies across the world have condemned it.
To describe puberty blockers as potentially performing the same function as conversion therapy is not just wrong: it takes something that causes harm and applies its name to something that prevents harm. It also implies, without ever quite saying it, that a trans young person's identity is the thing that needs to be prevented from taking hold. That is not a neutral clinical observation. It reflects a particular view of trans identity, one that sees it as a problem to be managed rather than a reality to be supported.
Why the international community rejected this framing
Gender specialists and researchers outside the UK were not slow to respond. Clinicians in the Netherlands, Sweden, Finland, Australia, Canada, and the United States published critiques, signed open letters, and gave interviews making clear that the Cass Review did not reflect the evidence base as they understood it, and that its conclusions were not ones their own services could recognise as grounded in the clinical reality they had observed over decades.
The World Professional Association for Transgender Health, known as WPATH, which publishes the Standards of Care that guide gender-affirming practice internationally, did not endorse the Cass Review's conclusions. The Endocrine Society, which publishes widely used clinical guidelines on hormone therapy, has continued to support puberty blockers as an appropriate intervention for trans young people experiencing gender dysphoria. The American Academy of Pediatrics, the American Academy of Child and Adolescent Psychiatry, and other major clinical bodies have maintained their support for gender-affirming care. The American Academy of Child and Adolescent Psychiatry reaffirmed its support for evidence-based gender-affirming care in 2025, directly in response to growing political pressure to restrict it.
Many gender medicine researchers published detailed, point-by-point rebuttals of the Cass Review's methodology and findings. These were not political documents. They were careful, evidence-based analyses from clinicians and researchers who had spent careers in this field and found the review's conclusions unrecognisable when set against the evidence they worked with every day.
What the ban on puberty blockers has actually done
The practical consequence of taking the Cass Review's conclusions at face value has been a ban on the sale and supply of puberty blockers on private prescription to trans young people in the UK. NHS prescriptions have become almost impossible to obtain, partly because the services that would provide them have been shut down or severely restricted. Young people who were mid-treatment have lost access to medication that was managing their distress. Families have described watching their children go through puberty changes they had been told were being paused, with no warning and no alternative. Some young people have been able to access care abroad, but that option is available only to those with the financial means and the family support to make it happen.
Delay in gender-affirming care is not neutral. Unwanted puberty changes are not reversible in the way that a blocker's effects are. The distress that comes from watching your body develop in ways that feel profoundly wrong does not simply resolve with time: for many young people it intensifies, and the window in which a blocker could have made a meaningful difference closes. This is harm. It is measurable, it is real, and it was predictable from the evidence available at the time the policy decisions were made.
How to read a review that has been discredited
The Cass Review has not been discredited because people dislike its conclusions. It has been discredited because the international clinical and research community examined its methodology and found it flawed, examined its sources and found them skewed, and examined its conclusions and found they did not follow from its own evidence. That is what discrediting looks like in medicine, and it is a serious finding.
It does not mean that every question the review raised about evidence quality in gender medicine is illegitimate. It does mean that you cannot use this review as a reliable guide to what the evidence shows, and you certainly cannot use it as justification for removing care from young people who need it. Those are not the same thing, and collapsing them together has been one of the more dishonest moves in the political debate around this topic.
If you are trying to understand the actual state of the evidence on puberty blockers and gender-affirming care for young people, the places to look are the published guidelines from WPATH, the Endocrine Society, and the major paediatric and psychiatric bodies. They do not tell a story of uncertainty and danger. They tell a story of a care pathway that has helped a great many young people, that carries risks which are well understood and manageable, and that is supported by decades of clinical experience across multiple countries.
Comments